IDKmonitor® Infliximab Total ADA ELISA

The IDKmonitor® Infliximab Total ADA ELISA is intended for the determination of human antibodies against TNF-alpha blocker infliximab (e.g. REMICADE®) in the presence of infliximab in EDTA plasma and serum.

For research use only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

If you’re in Canada, we offer a Health Canada Licensed version of this kit: K9654

Manufactured by Immundiagnostik AG.

Also available:

• Infliximab Free ADA ELISA: KR9650
• Infliximab Free ADA ELISA (Health Canada): K9650
• Infliximab Drug Level ELISA: KR9655
• Infliximab Drug Level ELISA (Health Canada): K9655

Test Principle of the IDKmonitor^® Infliximab Total ADA ELISA

This ELISA is used for the determination of antibodies against TNFα-Blocker infliximab (e. g. REMICADE®).

During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody to acquire free ADA. By adding the conjugate (peroxidase-labeled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced, and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin-coated microtiter plate. It is detected via the peroxidase conjugate, with the peroxidase converting the substrate TMB to a blue product.

Adding an acidic solution stops the enzymatic reaction. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.